# A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma

> **NCT07869043** · PHASE3 · RECRUITING · sponsor: **Pfizer** · enrollment: 1100 (estimated)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** tilrekimig
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07869043
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-09-30
- **Primary completion:** 2029-06-07
- **Final completion:** 2029-08-30
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2026-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07869043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07869043, "A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe Asthma". Retrieved via MORVS 2026-11-22 from https://api.morvs.ai/clinical/NCT07869043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*
